GO:0005275 amine transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005275 amine transmembrane transporter activity enables the transfer of amines, including polyamines, across biological membranes, as defined by QuickGO.
• This activity is mediated by diverse protein families, including P5B-ATPases, Na+/Cl- neurotransmitter transporters, and dopamine transporters.
• Amine transporters are critical for neurotransmitter reuptake, polyamine homeostasis, and lipid metabolism, with roles in neurological and metabolic disorders.
• Structural and mechanistic studies have revealed distinct transport mechanisms, such as the alternating access model for P5B-ATPases and the binding of inhibitors to dopamine transporters.
• Dysregulation of amine transporters is implicated in diseases such as Parkinson's disease, depression, and cancer, making them key therapeutic targets.
• CRISPR-based models, including knockout, point mutation, and knock-in, are essential for dissecting the function of amine transporters in health and disease.
Description
Amine transmembrane transporter activity (GO:0005275) is a molecular function that enables the movement of amines, including polyamines, across cellular membranes. Amines are organic compounds containing an amino group, and their transport is vital for numerous physiological processes, from neurotransmitter signaling to polyamine homeostasis. This activity is carried out by a diverse array of membrane proteins, such as neurotransmitter transporters and P5B-ATPases, which couple substrate translocation to ion gradients or ATP hydrolysis. Understanding the molecular mechanisms of amine transporters is crucial for elucidating their roles in health and disease, and for developing targeted therapies. Recent advances in structural biology and CRISPR-based gene editing have provided unprecedented insights into how these transporters function and how their dysfunction contributes to pathologies.
amine transmembrane transporter activity At A Glance
| GO ID | GO:0005275 |
|---|---|
| GO term | amine transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | amine/amide/polyamine channel activity; amine/polyamine transmembrane transporter activity; amino acid-polyamine transmembrane transporter activity |
| Major function | Enables the transfer of amines, including polyamines, across membranes |
| Definition | Enables the transfer of amines, including polyamines, from one side of a membrane to the other. Amines are organic compounds that are weakly basic in character and contain an amino (-NH2) or substituted amino group. |
| Related transporters | P5B-ATPases, Na+/Cl- neurotransmitter transporters, dopamine transporter |
| Cellular location | Membrane (plasma membrane or organelle membranes) |
What Is GO:0005275?
According to the Gene Ontology, amine transmembrane transporter activity (GO:0005275) is defined as the transfer of amines, including polyamines, from one side of a membrane to the other. Amines are weakly basic organic compounds that contain an amino (-NH2) or substituted amino group. This activity is synonymous with amine/amide/polyamine channel activity, amine/polyamine transmembrane transporter activity, and amino acid-polyamine transmembrane transporter activity.
Why Is amine transmembrane transporter activity Important in Cell Biology?
Amine transmembrane transporter activity is fundamental to cellular physiology because it regulates the concentration of amines and polyamines, which are involved in processes such as neurotransmission, cell growth, and stress responses. Dysfunction of these transporters is linked to a range of human diseases, including neurological disorders, metabolic conditions, and cancer. Therefore, studying this activity provides critical insights into disease mechanisms and offers potential targets for therapeutic intervention.
• Regulates neurotransmitter levels in the synaptic cleft, impacting mood, cognition, and motor control.
• Controls polyamine homeostasis, which is essential for cell proliferation and differentiation.
• Plays a role in lipid metabolism and membrane composition, as seen with CFTR and lipid interactions.
• Involved in the transport of l-carnitine, a key molecule for fatty acid oxidation.
• Dysfunction is associated with neurodegenerative diseases such as Parkinson's disease.
• Implicated in cancer through altered polyamine transport and metabolism.
• Targeted by antidepressants and psychostimulants that inhibit monoamine transporters.
• Provides a model system for studying membrane protein structure and mechanism.
• Potential for developing fluorescent probes to monitor transporter activity in cells.
• Relevant to viral entry and lipid-dependent processes, as retroviruses interact with lipids.
What Happens During amine transmembrane transporter activity?
Substrate Recognition and Binding
In simple terms: The transporter first grabs the amine molecule it needs to move.
Amine transporters selectively bind their substrates, such as neurotransmitters or polyamines, through specific amino acid residues in the binding pocket. For example, the human dopamine transporter recognizes dopamine via a central binding site that is also targeted by inhibitors. Similarly, P5B-ATPases bind their amine substrates with high specificity, as revealed by structural studies.
Conformational Changes and Translocation
In simple terms: The transporter changes shape to push the amine across the membrane.
Upon substrate binding, transporters undergo conformational changes that move the substrate across the lipid bilayer. The alternating access mechanism is a common model, where the transporter switches between outward-facing and inward-facing states. For Na+/Cl- neurotransmitter transporters, ion gradients drive these conformational transitions.
Energy Coupling and Driving Forces
In simple terms: Some transporters use ATP or ion gradients as fuel to move amines.
Amine transport can be powered by ATP hydrolysis, as in P5B-ATPases, or by coupling to ion gradients, as in Na+/Cl- neurotransmitter transporters. The energy source determines the direction and efficiency of transport, and defects in coupling can lead to disease.
Substrate Release and Reset
In simple terms: After delivering the amine, the transporter resets to pick up another.
Following translocation, the substrate is released on the other side of the membrane, and the transporter returns to its initial conformation. This cycle is essential for continuous transport and is regulated by cellular signals.
Key Genes Involved in GO:0005275 amine transmembrane transporter activity
The following genes encode proteins that exhibit amine transmembrane transporter activity, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC6A3 | Dopamine transporter; reuptakes dopamine from synapse | Target for psychostimulants; implicated in Parkinson's disease |
| SLC6A2 | Norepinephrine transporter; regulates norepinephrine | Target for antidepressants; involved in mood disorders |
| SLC6A4 | Serotonin transporter; reuptakes serotonin | Target for SSRIs; linked to depression and anxiety |
| ATP13A2 | P5B-ATPase; transports polyamines | Mutations cause Kufor-Rakeb syndrome; role in neurodegeneration |
| ATP13A3 | P5B-ATPase; polyamine transport | Potential role in cancer and polyamine homeostasis |
| ATP13A4 | P5B-ATPase; amine transport | Associated with neurodevelopmental disorders |
| ATP13A5 | P5B-ATPase; amine transport | Less studied; potential role in polyamine transport |
| SLC7A1 | Cationic amino acid transporter; transports amines | Involved in arginine transport and nitric oxide synthesis |
| SLC7A2 | Cationic amino acid transporter | Regulates immune function and polyamine synthesis |
| SLC3A2 | Heavy chain of amino acid transporters | Partners with light chains to transport amines |
| SLC6A1 | GABA transporter; reuptakes GABA | Target for antiepileptic drugs |
| SLC6A5 | Glycine transporter; reuptakes glycine | Involved in inhibitory neurotransmission |
| SLC6A9 | Glycine transporter; regulates glycine levels | Linked to hyperekplexia |
| SLC18A1 | Vesicular monoamine transporter; packages amines into vesicles | Target for reserpine; involved in monoamine storage |
| SLC18A2 | Vesicular monoamine transporter; packages amines into vesicles | Target for tetrabenazine; linked to Parkinson's disease |
| SLC22A1 | Organic cation transporter; transports amines | Involved in drug disposition and polyamine transport |
| SLC22A2 | Organic cation transporter; transports amines | Renal secretion of amines; drug interactions |
| SLC22A3 | Organic cation transporter; transports amines | Role in monoamine clearance |
How Is amine transmembrane transporter activity Regulated?
Amine transmembrane transporter activity is regulated at multiple levels, including transcriptional control, post-translational modifications, and membrane trafficking. For example, the dopamine transporter is regulated by phosphorylation and ubiquitination, which affect its surface expression and activity. Additionally, lipid composition can influence transporter function, as seen with CFTR and its interaction with lipids. Polyamine transport by P5B-ATPases is regulated by cellular polyamine levels and feedback mechanisms.
amine transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC6A3 | Parkinson's disease; dopamine dysregulation | Knockout mouse; point mutation of binding site |
| ATP13A2 | Kufor-Rakeb syndrome; neurodegeneration | Knock-in of patient mutations; knockout cell line |
| SLC6A4 | Depression; anxiety | Knockout rat; overexpression in cell lines |
| SLC22A1 | Drug disposition; cancer | Knockout organoids; tagged knock-in for localization |
| ATP13A3 | Cancer; polyamine homeostasis | CRISPR knockout in cancer cell lines; overexpression |
Neurodegenerative Disorders
Dysfunction of amine transporters is implicated in neurodegenerative diseases such as Parkinson's disease, where dopamine transporter activity is reduced due to loss of dopaminergic neurons. Mutations in ATP13A2, a polyamine transporter, cause Kufor-Rakeb syndrome, a form of early-onset Parkinsonism. These findings highlight the importance of amine transport in neuronal survival and function.
Psychiatric Disorders
Alterations in monoamine transporter activity are associated with depression, anxiety, and attention-deficit hyperactivity disorder. The serotonin transporter (SLC6A4) is a primary target for selective serotonin reuptake inhibitors, and polymorphisms in its gene affect treatment response. Similarly, the norepinephrine transporter is targeted by tricyclic antidepressants.
Cancer and Metabolic Diseases
Polyamine transporters are often upregulated in cancer cells to support rapid proliferation, making them potential therapeutic targets. Additionally, l-carnitine transport, which involves amine transporters, is crucial for fatty acid oxidation, and its dysfunction can lead to metabolic disorders.
From amine transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of transporter loss on neurotransmitter levels? | Knockout mouse or cell line |
| How do disease-associated mutations affect transport activity? | Point mutation knock-in cell lines |
| Where is the transporter localized in vivo? | Tagged knock-in (e.g., GFP) mouse |
| What is the effect of transporter overexpression on polyamine levels? | Overexpression cell lines |
| Can a candidate gene rescue transport in a knockout background? | Knock-in rescue model |
| What are the off-target effects of transporter inhibitors? | CRISPR library screening |
How to Study the amine transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | 3D structure of transporter | Understanding conformational changes |
| Radioligand binding | Affinity and density of transporters | Drug screening |
| Fluorescent transport assay | Real-time transport activity | Monitoring transporter function in live cells |
| CRISPR knockout | Loss-of-function phenotype | Determining gene essentiality |
| Site-directed mutagenesis | Effect of specific residues on transport | Mapping binding sites |
| RNA-seq | Gene expression changes | Identifying regulatory pathways |
| Proteomics | Protein interactions and modifications | Discovering regulatory partners |
| Patch clamp | Ion currents coupled to transport | Electrophysiology of transporters |
Structural Biology
Cryo-electron microscopy and X-ray crystallography have been used to determine the structures of amine transporters, such as the dopamine transporter and P5B-ATPases, revealing their substrate binding sites and conformational states.
Transport Assays
Radiolabeled substrate uptake assays and fluorescent probes are commonly used to measure amine transport activity in cells and membrane vesicles. These assays can be adapted for high-throughput screening of inhibitors.
Genetic Manipulation
CRISPR/Cas9-mediated knockout, point mutation, and knock-in models allow researchers to dissect the specific roles of amine transporters in cellular and animal systems. These models are complemented by overexpression studies to assess gain-of-function effects.
Omics Approaches
Transcriptomics and proteomics can reveal changes in amine transporter expression and post-translational modifications under different conditions, providing insights into regulatory mechanisms.
How CRISPR Can Be Used to Study GO:0005275 amine transmembrane transporter activity
Knockout
CRISPR knockout of amine transporter genes, such as SLC6A3 or ATP13A2, can abolish transport activity and reveal its contribution to cellular processes and disease phenotypes. These models are valuable for validating drug targets and understanding compensatory mechanisms.
Point Mutation
Introducing disease-associated point mutations (e.g., in SLC6A3 or ATP13A2) via CRISPR allows researchers to study the functional impact of specific amino acid changes on transporter activity, trafficking, and interactions.
Knock-in
Knock-in of tagged transporters (e.g., GFP or HA) enables visualization and biochemical isolation of the transporter in its native context, facilitating studies of localization, dynamics, and interactome.
Overexpression
CRISPR activation or cDNA overexpression can increase transporter levels, which is useful for studying gain-of-function effects, substrate specificity, and for producing protein for structural studies.
How EDITGENE Supports amine transmembrane transporter activity Research
Researchers studying amine transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in a specific physiological or pathological process. This requires precise genetic models that can knockout, mutate, or tag the gene of interest. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such research.
Contact EDITGENE today to design your custom CRISPR model for amine transmembrane transporter activity research.
Frequently Asked Questions About amine transmembrane transporter activity
What is amine transmembrane transporter activity?
It is a molecular function (GO:0005275) that enables the transfer of amines, including polyamines, across biological membranes, as defined by the Gene Ontology.
What genes are involved in amine transmembrane transporter activity?
Genes include SLC6A3 (dopamine transporter), SLC6A4 (serotonin transporter), ATP13A2 (polyamine transporter), and many others in the SLC and ATP13A families.
How is amine transmembrane transporter activity regulated?
It is regulated by transcriptional control, post-translational modifications, membrane trafficking, and lipid composition.
What diseases are associated with amine transporters?
Diseases include Parkinson's disease, depression, anxiety, and cancer, linked to dysfunction of dopamine, serotonin, and polyamine transporters.
What methods are used to study amine transporters?
Methods include cryo-EM, radioligand binding, fluorescent transport assays, CRISPR knockout, and omics approaches.
Can CRISPR be used to study amine transporters?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect amine transporter function and disease mechanisms.
What is the role of polyamine transporters in cancer?
Polyamine transporters are often upregulated in cancer to support cell proliferation, making them potential therapeutic targets.
How do antidepressants target amine transporters?
Antidepressants such as SSRIs inhibit serotonin transporters, increasing serotonin levels in the synapse.
What is the structure of a typical amine transporter?
Structures vary; for example, the dopamine transporter has 12 transmembrane helices and binds substrates in a central pocket.
Where can I find validated CRISPR models for amine transporter genes?
EDITGENE provides custom CRISPR models for knockout, point mutation, knock-in, and overexpression of amine transporter genes.
Conclusion
Amine transmembrane transporter activity (GO:0005275) is a fundamental molecular function that governs the movement of amines and polyamines across membranes, impacting neurotransmission, cell growth, and metabolism. Dysregulation of these transporters is linked to major human diseases, including neurodegenerative and psychiatric disorders, and cancer. Advances in structural biology and CRISPR-based gene editing continue to unravel the mechanisms and therapeutic potential of these transporters. EDITGENE offers comprehensive services to support research in this field, from custom CRISPR models to high-throughput screening.
References
- 1. Li P et al.. 2021. Structure and transport mechanism of P5B-ATPases.. Nat Commun 12(1):3973 PMID: 34172751
- 2. Srivastava DK et al.. 2024. Structure of the human dopamine transporter and mechanisms of inhibition.. Nature 632(8025):672-677 PMID: 39112705
- 3. Adeva-Andany MM et al.. 2017. Significance of l-carnitine for human health.. IUBMB Life 69(8):578-594 PMID: 28653367
- 4. Dohi T et al.. 2002. [Pharmacology of monoamine neurotransmitter transporters].. Nihon Yakurigaku Zasshi 120(5):315-26 PMID: 12491807
- 5. Cottrill KA et al.. 2020. The bidirectional relationship between CFTR and lipids.. Commun Biol 3(1):179 PMID: 32313074
- 6. Raulin J. 2000. Lipids and retroviruses.. Lipids 35(2):123-30 PMID: 10757541
- 7. Giri D et al.. 2024. A Highly Selective Fluorescent Probe for Monitoring the Thyroid Hormone Transporter Activity in Mammalian Cells.. Chemistry 30(54):e202401719 PMID: 38995511
- 8. Nelson N. 1998. The family of Na+/Cl- neurotransmitter transporters.. J Neurochem 71(5):1785-803 PMID: 9798903
